A randomized clinical trial was conducted to compare the effect of vitamin C vs. placebo on improving pulmonary function in newborns of pregnant smokers; and to test if this effect differed by maternal genotype.
A randomized clinical trial was conducted to compare the effect of vitamin C vs. placebo on improving pulmonary function in newborns of pregnant smokers; and to test if this effect differed by maternal genotype. (1) Vitamin C improved pulmonary function in newborns compared to placebo (TPTEF:TE ratio 0.383 vs 0.345; p = 0.006); and this effect was stronger in newborns with mothers with a specific genotype (p-interaction < 0.001).
(1)
BACKGROUND
When conducting clinical trials, investigators examine the effect of interventions on outcomes in the study population and often in subgroups of patients defined by baseline characteristics (e.g., demographics, prognostic factors). The goal is to understand if the magnitude of the effect of the intervention differs within categories of a subgroup; in our example, genotype subgroups. If the effect is different within subgroups we call this effect modification of the intervention on the outcome due to the additional presence of the subgroup variable. We commonly conduct a test for interaction, using multivariable models, to evaluate for statistically significant subgroup differences. If the p value is significant, we conclude that the effect of the intervention on the outcome differs within subgroups, in our example, maternal genotype.
Understanding treatment effects across patient subgroups is important because it helps identify patient groups that respond better or worse to the intervention. However, subgroup analyses should be done with caution to avoid common mistakes that either lead to false negative or positive findings, especially when they are not pre-specified in the analysis plan before starting the study. A common mistake is to compare the effect of treatment on the outcome separately within each subgroup. For example, comparing the effect of vitamin C vs. placebo on pulmonary function in newborns among mothers with one genotype and then separately among the mothers with another genotype. This approach is incorrect because it leads to multiple testing, which means that instead of using only one calculation to test for differences in effect across subgroups (p for interaction across genotype-groups in our example), we use two or more different calculations for each subgroup analysis. Every time we add a calculation, we no longer can use the standard significant level of p < 0.05. In this case, since there are two calculations we would need to divide the p value by 2 and use p < 0.025 as the significance level.
(2) Thus, we would overestimate subgroup differences if we kept the significance level at 0.05. Another challenge with subgroup analysis is that results may suggest that there are subgroup differences but the p-value is not statistically significant because the sample size within each subgroup is too small (Figure 1 ). Consider a hypothetical randomized trial with 30 participants, 15 in the treatment group (9 men and 6 women) and 15 in the control group (7 men and 8 women). To test if the effect of treatment differs between men and women, the correct approach is to use a multivariate model including an interaction term (treatment vs. sex), but with 30 participants, such a model would probably be underpowered to detect clinically significant differences. Comparing the effect of treatment vs. control in women only (6 vs. 8 participants), then in men only (7 vs. 8 participants) would also be underpowered.
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